https://www.biospace.com/hematology Hematology en-US Mon, 08 Jun 2026 08:48:08 GMT https://www.biospace.com/press-releases/amphista-therapeutics-announces-fda-clearance-of-ind-application-for-amx-883-its-lead-targeted-glue-degrader-for-acute-myeloid-leukaemia Mon, 08 Jun 2026 08:48:08 GMT https://www.biospace.com/press-releases/amphista-therapeutics-announces-fda-clearance-of-ind-application-for-amx-883-its-lead-targeted-glue-degrader-for-acute-myeloid-leukaemia https://www.biospace.com/press-releases/independent-market-research-finds-strong-physician-intent-to-prescribe-moleculins-annamycin-in-relapsed-refractory-aml Fri, 05 Jun 2026 12:50:27 GMT https://www.biospace.com/press-releases/independent-market-research-finds-strong-physician-intent-to-prescribe-moleculins-annamycin-in-relapsed-refractory-aml https://www.biospace.com/press-releases/lyell-immunopharma-to-present-phase-1-2-safety-and-translational-data-for-ronde-cel-in-large-b-cell-lymphoma-at-the-european-hematology-association-2026-congress Fri, 05 Jun 2026 07:17:12 GMT https://www.biospace.com/press-releases/lyell-immunopharma-to-present-phase-1-2-safety-and-translational-data-for-ronde-cel-in-large-b-cell-lymphoma-at-the-european-hematology-association-2026-congress https://www.biospace.com/press-releases/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israeli-ministry-of-health-to-conduct-exploratory-investigator-initiated-study-of-dnase-i-in-combination-with-anti-cd19-car-t-cells-in-large-b-cell-lymphoma Thu, 04 Jun 2026 13:13:12 GMT https://www.biospace.com/press-releases/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israeli-ministry-of-health-to-conduct-exploratory-investigator-initiated-study-of-dnase-i-in-combination-with-anti-cd19-car-t-cells-in-large-b-cell-lymphoma https://www.biospace.com/press-releases/alex-a-rod-rodriguez-to-deliver-special-remarks-at-the-foundation-for-sickle-cell-disease-researchs-20th-annual-sickle-cell-disease-research-and-educational-symposium-and-49th-national-sickle-cell-disease-scientific-meeting Thu, 04 Jun 2026 12:58:42 GMT https://www.biospace.com/press-releases/alex-a-rod-rodriguez-to-deliver-special-remarks-at-the-foundation-for-sickle-cell-disease-researchs-20th-annual-sickle-cell-disease-research-and-educational-symposium-and-49th-national-sickle-cell-disease-scientific-meeting https://www.biospace.com/press-releases/lupeng-pharmaceuticals-fourth-generation-btk-inhibitor-rocbrutinib-approved-in-china-for-relapsed-or-refractory-mantle-cell-lymphoma Thu, 04 Jun 2026 10:51:23 GMT https://www.biospace.com/press-releases/lupeng-pharmaceuticals-fourth-generation-btk-inhibitor-rocbrutinib-approved-in-china-for-relapsed-or-refractory-mantle-cell-lymphoma https://www.biospace.com/press-releases/taiho-oncology-announces-new-england-journal-of-medicine-publication-of-first-all-oral-regimen-in-newly-diagnosed-acute-myeloid-leukemia Thu, 04 Jun 2026 06:01:23 GMT https://www.biospace.com/press-releases/taiho-oncology-announces-new-england-journal-of-medicine-publication-of-first-all-oral-regimen-in-newly-diagnosed-acute-myeloid-leukemia https://www.biospace.com/press-releases/blood-cancer-treatment-allows-hard-to-match-kidney-failure-patients-to-receive-a-compatible-kidney-transplant Thu, 04 Jun 2026 05:53:04 GMT https://www.biospace.com/press-releases/blood-cancer-treatment-allows-hard-to-match-kidney-failure-patients-to-receive-a-compatible-kidney-transplant https://www.biospace.com/press-releases/adc-therapeutics-announces-results-from-lotis-5-phase-3-confirmatory-clinical-trial-of-zynlonta-in-combination-with-rituximab-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma Thu, 04 Jun 2026 05:50:25 GMT https://www.biospace.com/press-releases/adc-therapeutics-announces-results-from-lotis-5-phase-3-confirmatory-clinical-trial-of-zynlonta-in-combination-with-rituximab-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma https://www.biospace.com/press-releases/mission-bios-tapestri-enables-single-cell-profiling-of-residual-disease-identifying-aml-patients-likely-to-benefit-from-motixafortide-in-the-multicenter-blast-trial Thu, 04 Jun 2026 05:33:54 GMT https://www.biospace.com/press-releases/mission-bios-tapestri-enables-single-cell-profiling-of-residual-disease-identifying-aml-patients-likely-to-benefit-from-motixafortide-in-the-multicenter-blast-trial https://www.biospace.com/press-releases/ryan-clark-to-deliver-warrior-keynote-at-the-foundation-for-sickle-cell-disease-researchs-20th-annual-sickle-cell-disease-research-and-educational-symposium-and-49th-national-sickle-cell-disease-scientific-meeting Thu, 04 Jun 2026 02:06:45 GMT https://www.biospace.com/press-releases/ryan-clark-to-deliver-warrior-keynote-at-the-foundation-for-sickle-cell-disease-researchs-20th-annual-sickle-cell-disease-research-and-educational-symposium-and-49th-national-sickle-cell-disease-scientific-meeting https://www.biospace.com/press-releases/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl Wed, 03 Jun 2026 04:31:01 GMT https://www.biospace.com/press-releases/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl https://www.biospace.com/press-releases/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-june-1-2026 Mon, 01 Jun 2026 13:56:40 GMT https://www.biospace.com/press-releases/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-june-1-2026 https://www.biospace.com/press-releases/geron-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference Mon, 01 Jun 2026 13:47:17 GMT https://www.biospace.com/press-releases/geron-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference https://www.biospace.com/press-releases/bristol-myers-squibb-announces-opdivo-nivolumab-in-combination-with-avd-receives-expanded-eu-label-with-approval-in-frontline-advanced-classical-hodgkin-lymphoma Mon, 01 Jun 2026 11:25:10 GMT https://www.biospace.com/press-releases/bristol-myers-squibb-announces-opdivo-nivolumab-in-combination-with-avd-receives-expanded-eu-label-with-approval-in-frontline-advanced-classical-hodgkin-lymphoma https://www.biospace.com/press-releases/bioinvent-to-host-a-kol-event-in-stockholm-on-june-11-2026-to-discuss-updated-bi-1206-bi-1808-data-in-hematology Mon, 01 Jun 2026 11:04:32 GMT https://www.biospace.com/press-releases/bioinvent-to-host-a-kol-event-in-stockholm-on-june-11-2026-to-discuss-updated-bi-1206-bi-1808-data-in-hematology https://www.biospace.com/press-releases/agios-enters-exclusive-global-license-agreement-with-oscotec-to-develop-and-commercialize-next-generation-syk-inhibitor-cevidoplenib Mon, 01 Jun 2026 11:02:13 GMT https://www.biospace.com/press-releases/agios-enters-exclusive-global-license-agreement-with-oscotec-to-develop-and-commercialize-next-generation-syk-inhibitor-cevidoplenib https://www.biospace.com/press-releases/incytes-pivotal-frontmind-trial-showed-tafasitamab-monjuvi-minjuvi-combination-significantly-prolonged-progression-free-survival-reducing-the-risk-of-disease-progression-or-death-by-25-in-patients-with-previously-untreated-high-risk-dlbcl Mon, 01 Jun 2026 07:09:43 GMT https://www.biospace.com/press-releases/incytes-pivotal-frontmind-trial-showed-tafasitamab-monjuvi-minjuvi-combination-significantly-prolonged-progression-free-survival-reducing-the-risk-of-disease-progression-or-death-by-25-in-patients-with-previously-untreated-high-risk-dlbcl https://www.biospace.com/press-releases/abbvie-announces-european-commission-authorization-of-expanded-label-for-venclyxto-venetoclax-to-include-additional-combinations-in-previously-untreated-chronic-lymphocytic-leukemia Fri, 29 May 2026 14:00:59 GMT https://www.biospace.com/press-releases/abbvie-announces-european-commission-authorization-of-expanded-label-for-venclyxto-venetoclax-to-include-additional-combinations-in-previously-untreated-chronic-lymphocytic-leukemia https://www.biospace.com/press-releases/daiichi-sankyo-concludes-pcpa-letter-of-intent-for-vanflyta-in-newly-diagnosed-flt3-itd-positive-aml Fri, 29 May 2026 03:54:31 GMT https://www.biospace.com/press-releases/daiichi-sankyo-concludes-pcpa-letter-of-intent-for-vanflyta-in-newly-diagnosed-flt3-itd-positive-aml